ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / XRAY / earnings
LMAT (69) KMTS (50) INSP (66) ATEC (46) ⌘ Pro Terminal →

DENTSPLY SIRONA Inc. (XRAY) Next Earnings Date & Expected ±7.7% Move

$9.53 -0.83% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.50

DENTSPLY SIRONA Inc. (XRAY) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $1.92B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XRAY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XRAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, DENTSPLY SIRONA Inc. (NASDAQ: XRAY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $9.53 (-0.83% 1D, market cap $1.92B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XRAY ranks #770 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XRAY compare to LMAT and KMTS in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), XRAY carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 50.0%, and ROIC of -11.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a C+ grade (69/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.95B) and KMTS (Kestra Medical Technologies Ltd.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.82B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XRAY?
▼

Per XRAY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818479), DENTSPLY SIRONA Inc. generated $3.68B in revenue (-3.0% YoY), -$598.0M in net income, and $235.0M in free cash flow against $5.43B in total assets and $2.02B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.50 (-0.34%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 6.4% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E
Cash (5)Whales (8)SEC (5)Macro (5)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
$16 Bull$8 Base$7 Bear
📬 FREE XRAY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XRAY)Realized 20D OHLCV Swing Band: ±7.7%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY XRAY SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+9/20 pts (28% of score)

SEC Form 4 / 13F Thermometer: 45% Net Buy • Disciplined Float (-0.40% YoY Shares)

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (25% of score)

20D Institutional Volume Accumulation (±7.7% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (56.5) create a -15 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
24
Grade E$8.53-1.3% Next Q
Q2 (-2Q)
27
Grade E$8.42+9.5% Next Q
Q3 (-1Q)
29
Grade E$9.22+3.4% Next Q
Current
32
Grade E$9.53-9.2% Hist 90D α
Trajectory: E (24) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XRAY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XRAY currently carries a cautious 32/100 (E) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.67) and Max Pain ($10.01) forces dealer call-delta covering toward $15.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XRAY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XRAY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±7.7% Swing Band

±$0.73 Expected Swing
$8.80 (-7.7%)Spot $9.53$10.26 (+7.7%)
MODEL EARNINGS SETUP GAUGE

XRAY Quantitative Pre-Earnings Setup: 32/100

Trailing EPS: $4.25 • YoY Revenue Growth: -3%

Model Bullish Setup (32/100)Model Risk Weight (68/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$3.68B-$598.0M$235.0M50%
FY 20242024-12-31$3.79B-$910.0M$461.0M51.6%
FY 20232023-12-31$3.96B-$132.0M$377.0M50%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XRAY)

  • ✓Walkthrough of XRAY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XRAY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.91%⚡ TESTING RESISTANCE
2026-11-02O $9.44H $9.61L $9.44C $9.53VOL 3.55M
RES: $9.67SUP: $8.19SMA50: $9.67SMA200: $11.32
$14.87$13.09$11.32$9.54$7.77RES $9.67SUP $8.19$9.532026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XRAY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XRAY Butterfly Map → + Track XRAY →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -3.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on XRAY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XRAY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XRAY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XRAY)

Health Care Rank #770 of 1016 ⚔️ LMAT vs XRAY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XRAY vs. LMAT, KMTS, INSP, ATEC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DENTSPLY SIRONA Inc. (XRAY) ranks #770 by composite RQD confidence (32/100, grade E) and #269 by equity capitalization ($1.92B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. LMAT currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with XRAY at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XRAY ACTIVE
DENTSPLY SIRONA Inc.
E 32/100 — 50.0% -11.0% -0.83% $1.92B Benchmark Subject
LMAT
LeMaitre Vascular Inc.
C+ 69/100 33.8x 71.5% 14.7% -5.08% $1.95B /lmat-vs-xray →
KMTS
Kestra Medical Technologies Ltd.
D 50/100 — 51.4% -35.0% -3.01% $1.82B /kmts-vs-xray →
INSP
Inspire Medical Systems Inc.
C+ 66/100 14.2x 85.4% 6.0% -4.33% $2.06B /insp-vs-xray →
ATEC
Alphatec Holdings Inc.
D 46/100 — 69.6% -18.4% -38.08% $1.76B /atec-vs-xray →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000818479

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DENTSPLY SIRONA Inc. (XRAY) reported GAAP revenue of $3.68B (-3.0% vs. FY2024 revenue of $3.79B , and -7.2% cumulative change since FY2023) , GAAP net income of -$598.0M, operating cash flow of $235.0M, and free cash flow of $235.0M (-49.0% YoY). On the balance sheet, XRAY closed FY2025 with $5.43B in total assets against $2.02B in total debt (Altman Z-Score: 0.45, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.68B -$598.0M $235.0M $235.0M $5.43B $2.02B
FY2024 (FY) 2024-12-31 $3.79B -$910.0M $461.0M $461.0M $5.75B $1.59B
FY2023 (FY) 2023-12-31 $3.96B -$132.0M $377.0M $377.0M — —

3. XRAY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XRAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, DENTSPLY SIRONA Inc. (NASDAQ: XRAY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $9.53 (-0.83% 1D, market cap $1.92B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, XRAY ranks #770 in composite RQD confidence.

How does XRAY compare to LMAT and KMTS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), XRAY carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 50.0%, and ROIC of -11.0%. By comparison, LMAT (LeMaitre Vascular Inc.) holds a C+ grade (69/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.95B) and KMTS (Kestra Medical Technologies Ltd.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.82B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XRAY?

Per XRAY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000818479), DENTSPLY SIRONA Inc. generated $3.68B in revenue (-3.0% YoY), -$598.0M in net income, and $235.0M in free cash flow against $5.43B in total assets and $2.02B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XRAY trading relative to its 50-day, 200-day, and 52-week technical levels?

XRAY last traded at $9.53 (-0.83% on volume of 3,497,223 shares), positioning the stock -1.45% below its 50-day simple moving average ($9.67) and -15.81% below its 200-day simple moving average ($11.32). Across its 52-week range of $8.32 to $14.76, XRAY sits at the 18.8% percentile with a 14-day RSI of 56.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.7% ($8.80 to $10.26).

XRAY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is XRAY's next earnings date?

Based on SEC filing cadence, DENTSPLY SIRONA Inc. (XRAY)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is XRAY stock expected to move on earnings?

Volatility modeling currently projects a ±7.7% event move for XRAY, spanning a range between $8.8 and $10.26.

Direct Sub-Reports: XRAY RQD Cockpit XRAY 12M Forecast XRAY Earnings & Move XRAY Dividends & DRIP XRAY Insiders & 13F XRAY Whale Options XRAY Profit Sankey XRAY News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

XRAY — DENTSPLY SIRONA Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:27:21Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, XRAY scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC of -11%, FCF yield of 12.27%); Whale 13F Flow at 8/20 (institutional accumulation and options positioning); Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 5/20 (Beta 1.0, sector sensitivity); and Forensic Balance Sheet at 5/20 (Altman Z 0.45, Piotroski F 6/9, Debt/Equity 1.5). The two weakest pillars, cash engine and balance sheet, sit on top of negative returns on capital and a low Altman Z, which together point to elevated financial-distress risk. The strongest pillar, insider and flow activity at 9/20, is still well below a constructive level. The high 12.27% FCF yield is the main valuation point in the bull case, but per the SEC financials it coexists with operating and net losses, so an investor would need to determine whether that cash generation is durable before weighting it heavily. Taken together, the rating frames XRAY as a name where forensic risk outweighs apparent cheapness.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$3680.0M$-422.0M$-598.0MN/A$235.0M$326.0M$2015.0M
FY 2024$3793.0M$-879.0M$-910.0MN/A$461.0M$272.0M$1586.0M
FY 2023$3965.0M$-85.0M$-132.0MN/A$377.0MN/AN/A

Per the SEC financials, revenue declined from $3965.0M (FY 2023) to $3680.0M (FY 2025), and the company reported operating losses in each period shown. Per the market data, operating margin is -11.5%, net margin is -16.2%, and ROIC is -11%. The Altman Z-Score is 0.45 and the Piotroski F-Score is 6/9, both per the Roarable RQD rating. Debt rose from $1586.0M to $2015.0M over the FY 2024 to FY 2025 periods, and the Debt/Equity ratio is 1.5 per the Roarable RQD rating.

Recent Catalysts & News Wire Analysis

Per the news feed, recent headlines cover a Midwest dental expansion described as a "reset story," post-Q2 earnings buy/sell/hold commentary, a Simply Wall St piece framing the stock as possibly cheap with sales in focus, and a MarketBeat report of a new 52-week low. A Stock Titan item notes a webcast to review third-quarter results on Nov. 5. All news items carry a YELLOW light and MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present. Risk watch items per the news and financial sections include the 52-week low, continued operating losses, and rising debt.

Open Questions

  • What are the drivers of the FY 2025 operating and net losses, and are they recurring or restructuring-related?
  • What is the source of the FCF generation given the reported operating losses, and is it sustainable?
  • How will the Q3 results referenced in the news feed affect the debt trajectory and Altman Z-Score?
  • What is the company's earnings per share and valuation multiple profile, given that P/E, EPS, and EV/EBITDA are unavailable?
  • Who holds the stock institutionally, and what are the 13F and insider transaction details?

XRAY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for DENTSPLY SIRONA Inc. (XRAY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XRAY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XRAY Bull vs. Bear Conversation Board — What's Your Call at $9.53?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XRAY 🐻 67% BEARISH CONVICTION
1. Pick Your Side on XRAY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $8.46 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is XRAY (E • RQD 32/100) a Buy at $9.61?

Welcome to the XRAY (DENTSPLY SIRONA Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $7.69 (-20.0%)
Spot @ $9.61

Pump the brakes on XRAY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on XRAY, but look at what you are paying: current EV/EBITDA multiples with 50.0% gross margins. Unless DENTSPLY SIRONA Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $11.34 (+18.0%)
Spot @ $9.61

XRAY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on XRAY, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $9.61 (52-wk range $8.32 - $14.76), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%